Component

Aberrant Behavior Checklist score, population specified

Aberrant Behavior Checklist score, population specified. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The active group showed a 34% ABC-score reduction at 18 weeks, with a significant between-treatment comparison.

    Sulforaphane / SFN, stereochemistry specified per study → Aberrant Behavior Checklist score, population specified source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/sulforaphane-research/25313065.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44", "start_char": 0, "end_char": 1872, "text_sha256": "d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44"}
    experimental_model
    Randomized double-blind placebo-controlled trial
    exposure
    Sulforaphane 50-150 micromol/day for 18 weeks, then four weeks off
    limitations
    Small male-only study; symptom-scale changes are not a cure and do not establish mechanism.
    nutrient_topic
    Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. · Sulforaphane / SFN, stereochemistry specified per study
    organism
    Human, 44 males aged 13-27, 29 active and 15 placebo
    plain_language
    One early trial reported improvement in this symptom scale.
    primary_references
    [sulforaphane-p25313065] Sulforaphane treatment of autism spectrum disorder (ASD). (2014). https://pubmed.ncbi.nlm.nih.gov/25313065/ DOI: 10.1073/pnas.1416940111
    tissue_or_cell_type
    ABC and SRS behavioral ratings

    Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17) · lines 1334–1345

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled trial · source_derived_draft · unverified_draft

    ### sulforaphane-autism-abc-early The active group showed a 34% ABC-score reduction at 18 weeks, with a significant between-treatment comparison. Condition category: normal nutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. plain_language: One early trial reported improvement in this symptom scale. organism: Human, 44 males aged 13-27, 29 active and 15 placebo tissue_or_cell_type: ABC and SRS behavioral ratings experimental_model: Randomized double-blind placebo-controlled trial limitations: Small male-only study; symptom-scale changes are not a cure and do not establish mechanism. exposure: Sulforaphane 50-150 micromol/day for 18 weeks, then four weeks off evidence_span: {"source_cache": "artifacts/sulforaphane-research/25313065.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44", "start_char": 0, "end_char": 1872, "text_sha256": "d6f39bcdb3d5d89fd9226e208c82da13d9f18fee2003a8c817c67da0e344fd44"} [sulforaphane-p25313065] Sulforaphane treatment of autism spectrum disorder (ASD). (2014). https://pubmed.ncbi.nlm.nih.gov/25313065/ DOI: 10.1073/pnas.1416940111
    Complete structured claim and evidence

  2. Caregiver ABC scores improved at 15 weeks, but SRS-2 did not significantly improve.

    Glucoraphanin plus active myrosinase preparation → Aberrant Behavior Checklist score, population specified source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/sulforaphane-research/34034808.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4", "start_char": 0, "end_char": 3223, "text_sha256": "1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4"}
    experimental_model
    Randomized double-blind trial followed by open-label and withdrawal phases
    exposure
    Glucoraphanin plus active myrosinase tablets, not preformed sulforaphane; 15 weeks randomized, 15 weeks open-label, six weeks off
    limitations
    Primary endpoint was nonsignificant. The published correction (PMID 34134777, DOI 10.1186/s13229-021-00451-9) clarifies the preparation: 34 micromol glucoraphanin per tablet, calculated to yield about 15 micromol sulforaphane. Open-label analyses are nonrandomized.
    nutrient_topic
    Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. · Sulforaphane / SFN, stereochemistry specified per study
    organism
    Human, 57 children aged 3-12 randomized; 45 analyzed
    plain_language
    Different secondary measures gave different results.
    primary_references
    [sulforaphane-p34034808] Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. (2021). https://pubmed.ncbi.nlm.nih.gov/34034808/ DOI: 10.1186/s13229-021-00447-5
    tissue_or_cell_type
    Primary OACIS and secondary caregiver ratings

    Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17) · lines 1373–1384

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind trial followed by open-label and withdrawal phases · source_derived_draft · unverified_draft

    ### sulforaphane-autism-secondary-abc Caregiver ABC scores improved at 15 weeks, but SRS-2 did not significantly improve. Condition category: normal nutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. plain_language: Different secondary measures gave different results. organism: Human, 57 children aged 3-12 randomized; 45 analyzed tissue_or_cell_type: Primary OACIS and secondary caregiver ratings experimental_model: Randomized double-blind trial followed by open-label and withdrawal phases limitations: Primary endpoint was nonsignificant. The published correction (PMID 34134777, DOI 10.1186/s13229-021-00451-9) clarifies the preparation: 34 micromol glucoraphanin per tablet, calculated to yield about 15 micromol sulforaphane. Open-label analyses are nonrandomized. exposure: Glucoraphanin plus active myrosinase tablets, not preformed sulforaphane; 15 weeks randomized, 15 weeks open-label, six weeks off evidence_span: {"source_cache": "artifacts/sulforaphane-research/34034808.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4", "start_char": 0, "end_char": 3223, "text_sha256": "1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4"} [sulforaphane-p34034808] Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. (2021). https://pubmed.ncbi.nlm.nih.gov/34034808/ DOI: 10.1186/s13229-021-00447-5
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards